Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice
暂无分享,去创建一个
R. Boidot | J. Pallandre | C. Borg | Y. Godet | J. Latouche | Mohamad Hamieh | T. al Saati | A. Asgarova | S. Valmary-Degano | O. Adotévi | M. Dosset | E. Lauret Marie Joseph | L. Rangan | J. Galaine | J. Francoual | Laurent Beziaud | Jean-René Pallandre | Afag Asgarova
[1] Andrew D. Rouillard,et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..
[2] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[3] T. Frebourg,et al. Artificial antigen‐presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4+ T cells , 2016, Immunology and cell biology.
[4] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[5] P. Rohrlich,et al. CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes , 2015, International journal of cancer.
[6] Michael Peyton,et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.
[7] Jun S. Wei,et al. The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.
[8] S. Stevanović,et al. A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.
[9] H. Saya,et al. Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis , 2014, Tumor Biology.
[10] F. Ghiringhelli,et al. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy , 2014, Expert review of clinical immunology.
[11] T. Meyer,et al. The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity , 2013, British Journal of Cancer.
[12] S. Buus,et al. HLA-A*01:03, HLA-A*24:02, HLA-B*08:01, HLA-B*27:05, HLA-B*35:01, HLA-B*44:02, and HLA-C*07:01 Monochain Transgenic/H-2 Class I Null Mice: Novel Versatile Preclinical Models of Human T Cell Responses , 2013, The Journal of Immunology.
[13] Jilong Yang,et al. Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas , 2013, Medical Oncology.
[14] E. Tartour,et al. Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor , 2012, Clinical Cancer Research.
[15] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[16] A. Pajot,et al. Development of a Humanized HLA-A2.1/DP4 Transgenic Mouse Model and the Use of This Model to Map HLA-DP4-Restricted Epitopes of HBV Envelope Protein , 2012, PloS one.
[17] A. Gritzapis,et al. Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice , 2012, Cancer Immunology, Immunotherapy.
[18] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[19] D. Schadendorf,et al. Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries , 2010, PloS one.
[20] Andrew R. Jones,et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..
[21] D. Legler,et al. Definition of Key Variables for the Induction of Optimal NY-ESO-1–Specific T Cells in HLA Transgene Mice , 2010, The Journal of Immunology.
[22] H. Vaudry,et al. HLA-A*0201-restricted CEA-derived Peptide CAP1 Is Not a Suitable Target for T-cell-based Immunotherapy , 2010, Journal of immunotherapy.
[23] E. Tartour,et al. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. , 2010, Blood.
[24] L. Zitvogel,et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. , 2006, The Journal of Immunology.
[25] P. Meltzer,et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. , 2005, Cancer research.
[26] S. Pascolo. HLA class I transgenic mice: development, utilisation and improvement , 2005, Expert opinion on biological therapy.
[27] A. Pajot,et al. A mouse model of human adaptive immune functions: HLA‐A2.1‐/HLA‐DR1‐transgenic H‐2 class I‐/class II‐knockout mice , 2004, European journal of immunology.
[28] P. Opolon,et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. , 2004, The Journal of clinical investigation.
[29] I. Svane,et al. Molecular aberrations in the MHC class I‐restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein , 1997, Clinical and experimental immunology.
[30] D. Leach,et al. Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity. , 1995, Journal of immunology.
[31] S. Segal,et al. Major histocompatibility complex class I genes in murine fibrosarcoma IC9 are down regulated at the level of the chromatin structure , 1989, Molecular and cellular biology.
[32] S. Ostrand-Rosenberg,et al. Tumor‐specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC‐class‐II genes or allogeneic MHC‐class‐I genes , 1991, International journal of cancer. Supplement = Journal international du cancer. Supplement.